Sentinel-node biopsy improved DFS, staging in melanoma

  • April 15, 2014

NEW YORK — Sentinel lymph node biopsy after wide excision improved DFS compared with wide excision alone among patients with intermediate and thick melanomas, according to final results of the MSLT-1 trial presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting in New York.

“We found that performing sentinel lymph node biopsy is very accurate and improves staging in order to determine whether additional treatments are needed, such as additional surgery or adjuvant systemic therapy,” Robert H.I. Andtbacka, MD, CM, FACS, FRCSC, associate professor of surgery at Huntsman Cancer Institute at the University of Utah, said during a presentation. “It also forms a basis for us to perform all the subsequent studies that we do in melanoma to make sure patients we have for our clinical trials are well balanced.”

More »

Additional headlines from HemOnc Today Melanoma and Cutaneous Malignancies meeting

See All »